US EditionPublished • loading... • Updated
Ailux Appoints Maria Belvisi, Ph.D., as Chief Scientific Officer
Belvisi will lead scientific strategy and new program development as Ailux targets first clinical entry by 2027, the company said.
- On Thursday, Ailux appointed Maria Belvisi as Chief Scientific Officer, tasking her with leading scientific strategy and establishing a new research site in the UK to complement Shanghai capabilities.
- Professor Belvski joins from AstraZeneca, where she served as Senior Vice President, Research & Development, Respiratory & Immunology and championed tozorakimab, an IL-33 antibody that recently met primary endpoints in two pivotal COPD trials.
- "What drew me to Ailux is the genuine integration of AI and biology," Belvski said. The company, a subsidiary of XtalPi, combines proprietary AI platforms with a 30,000 square foot wet lab.
- Her appointment accelerates Ailux's evolution from AI-native biologics discovery into a fully integrated drug development organization, with the global team of approximately 150 targeting first clinical entry by 2027.
- Alongside her industry work, Belvski maintains a professorship at Imperial College London and was named one of Endpoints News' "20 Outstanding Women in Biopharma" in 2021, bringing more than three decades of drug research leadership.
Insights by Ground AI
36 Articles
36 Articles
Bennington Banner+35 Reposted by 35 other sources
Ailux Appoints Maria Belvisi, Ph.D., as Chief Scientific Officer
Professor Belvisi joins from AstraZeneca, where she served as Senior Vice President, Research & Development, Respiratory & Immunology and built one of the most productive early R&D organizations in global pharma, including leading tozorakimab from preclinical research through Phase 3…
Coverage Details
Total News Sources36
Leaning Left5Leaning Right3Center12Last UpdatedBias Distribution60% Center
Bias Distribution
- 60% of the sources are Center
60% Center
L 25%
C 60%
15%
Factuality
To view factuality data please Upgrade to Premium
